Early results on rucaparib/sacituzumab govitecan are promising, but further exploration is needed, stated Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science, MD Anderson Cancer Center.
After presenting SEASTAR trial data at this year’s annual virtual ESMO meeting, Timothy A. Yap, MBBS, PhD, FRCP, medical director, Institute for Applied Cancer Science; associate professor, Department of Investigational Cancer Therapeutics (Phase I Program), Department of Thoracic/Head and Neck Medical Oncology; and associate director of Translational Research, Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, discusses the next steps in this investigation.
Transcript
What is the next step in the SEASTAR study?
These early results described in the presentation shared at ESMO suggest that further investigation is certainly warranted, though the dose and schedule to actually address the myelosuppression experienced by patients in this trial require further exploration. With the recent announcement of the Gilead acquisition of Immunomedics, my understanding is that Clovis looks forward to discussing potential further development of rucaparib in combination with sacituzumab govitecan with Gilead.
What is the timeline for implementing this combination if it is approved?
We’re only at the end of the phase 1B portion of the SEASTAR study, so it’s still early days. The combination will need to go through further clinical trial testing. It’s very difficult to predict timing for trial completion and regulatory approval. However, I can say that medical professionals and patients are very eager for new molecularly targeted agents that can address the still substantial unmet medical needs in solid tumors, such as triple-negative breast cancer.
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Lack of Vitamin D May Increase Chemo-Induced Neuropathy Risk in Breast Cancer
November 16th 2023Investigators note that prospective research is needed to confirm the efficacy of vitamin D supplements in preventing chemotherapy-induced peripheral neuropathy in patients with breast cancer.
Read More
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More